The thesis

PALI is a clinical-stage biopharmaceutical firm developing treatments for gastrointestinal conditions. The company's conviction score is 34/100, indicating low conviction. With a P/E ratio of -16.8x, PALI's valuation is a concern. The analyst consensus rating is BUY, but the DCF intrinsic value is only $2.

Why now

The current macro context, with China's chip tool push and the US-China squeeze, may impact PALI's ability to secure funding. The company's low conviction score and negative P/E ratio make it a compelling watchlist candidate right now.

What to watch

Investors should watch PALI's upcoming clinical trial results and updates on LB1148's development over the next quarter. The company's ability to secure funding and partnerships will also be crucial in confirming or denying the thesis.

Key risks

PALI faces valuation risk due to its negative P/E ratio and low DCF intrinsic value. The company is also exposed to execution risk, as its primary therapeutic candidate, LB1148, is still in clinical stages. Macro risk is another concern, as geopolitical tensions may affect the biopharmaceutical industry.